Revenue (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes our revenue recognized in our consolidated condensed statements of operations:

	Three Months Ended March 31,
	2021		2020
Net product revenue	$	6,320.0	$	5,403.5
Collaboration and other revenue (1)	485.6		456.3
Revenue	$	6,805.6	$	5,859.8

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $43.0 million and $35.4 million during the three months ended March 31, 2021 and 2020, respectively.

The following table summarizes revenue by product for the three months ended March 31, 2021 and 2020:

	Three Months Ended March 31,
	2021						2020
	U.S.		Outside U.S.		Total		U.S.		Outside U.S.		Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®	$	1,116.8	$	335.7	$	1,452.4	$	929.5	$	299.9	$	1,229.4
Humalog® (1)	332.7		284.4		617.0		398.6		297.2		695.8
Humulin®	219.0		102.7		321.7		214.1		101.5		315.7
Jardiance (2)	151.2		160.8		312.0		144.6		122.9		267.5
Basaglar®	175.2		71.4		246.6		230.4		73.3		303.7
Other Diabetes	66.3		94.9		161.4		74.0		82.9		156.8
Total Diabetes	2,061.2		1,049.9		3,111.1		1,991.2		977.7		2,968.9
Oncology:
Alimta®	261.1		297.8		559.0		324.2		235.8		560.1
Verzenio®	172.8		96.2		269.0		129.4		58.6		188.0
Cyramza®	80.2		160.3		240.5		89.1		149.9		239.0
Erbitux®	107.9		14.4		122.4		117.8		13.0		130.8
Tyvyt®	—		109.7		109.7		—		57.4		57.4
Other Oncology	20.5		51.3		71.6		(2.6)		28.9		26.2
Total Oncology	642.5		729.7		1,372.2		657.9		543.6		1,201.5
Immunology:
Taltz®	249.6		153.6		403.2		327.5		116.0		443.5
Olumiant®	24.7		169.1		193.8		11.3		128.4		139.7
Other Immunology	10.5		6.4		16.9		2.6		—		2.6
Total Immunology	284.8		329.1		613.9		341.4		244.4		585.8
Neuroscience:
Cymbalta®	11.0		165.7		176.6		11.6		198.8		210.4
Emgality®	101.5		18.0		119.5		67.3		6.7		74.0
Zyprexa®	6.9		88.9		95.8		11.2		87.2		98.4
Other Neuroscience	22.3		51.1		73.5		20.2		60.5		80.7
Total Neuroscience	141.7		323.7		465.4		110.3		353.2		463.5
Other:
COVID-19 Antibodies (3)	650.6		159.5		810.1		—		—		—
Forteo®	97.7		100.8		198.5		122.5		149.8		272.4
Cialis®	8.6		118.1		126.8		26.1		167.0		193.0
Other	54.2		53.4		107.5		79.4		95.3		174.7
Total Other	811.1		431.8		1,242.9		228.0		412.1		640.1
Revenue	$	3,941.3	$	2,864.3	$	6,805.6	$	3,328.8	$	2,531.0	$	5,859.8

Numbers may not add due to rounding.

(1) Humalog revenue includes insulin lispro.

(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.

(3) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUAs).

The following table summarizes revenue by geographical area:

	Three Months Ended March 31,
	2021		2020
Revenue—to unaffiliated customers (1):
U.S.	$	3,941.3	$	3,328.8
Europe	1,321.2		1,061.0
Japan	571.8		592.3
China	362.2		267.3
Other foreign countries	609.1		610.4
Revenue	$	6,805.6	$	5,859.8

Numbers may not add due to rounding.

(1) Revenue is attributed to the countries based on the location of the customer.

Schedule of amounts recorded for contract liabilities

The following table summarizes contract liability balances:

	March 31, 2021		December 31, 2020
Contract liabilities	$	346.6	$	276.8